drugset / Trial / NCT01248247
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
334 enrolled
M.D. Anderson Cancer Center
GlaxoSmithKline · collabMerck Sharp & Dohme LLC · collabNational Cancer Institute (NCI) · collabNovartis · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
Different people have different biomarkers (chemical "markers" in the blood that may be related to your reaction to study drugs). If researchers know about your biomarkers before you receive treatment, they may be able to prescribe a treatment that is better suited to your body's specific needs. The goal of this clinical research study is to learn if drug or drug combinations based on your biomarkers can help to control NSCLC. The safety of these drug combinations will also be studied.
Timeline
- Start
- 2011-06-02
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | MK-2206 | Small molecule | 100 mg | Oral |
| Subject | MK-2206 | Small molecule | 135 mg | Oral |
| Subject | Selumetinib | Small molecule | 100 mg | Oral |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |